Schedule of Events
Sunday, October 21 (all times are ET)
-- TAXUS ARRIVE data. Two-year follow-up data and sub-group analysis from
the TAXUS ARRIVE registry will be presented by John M. Lasala, M.D.,
PhD, at the DES Summit at 1:19 p.m. in Ballroom C of the Washington
Convention Center. The ARRIVE program is designed to collect and
analyze "real-world" safety and clinical outcomes data from the TAXUS
Express2 Paclitaxel-Eluting Stent System in the treatment of patients
with coronary artery disease. The Company plans to issue a press
release at this time.
Monday, October 22
-- Spirit III Clinical Trial Results -- XIENCE V (PROMUS) Stent and TAXUS
Stent. At 12:15 p.m., one-year data from Abbott's Spirit III Clinical
Trial will be presented by Gregg W. Stone, M.D., at a late-breaking
trial session in the main arena. Dr. Stone will provide an updated
analysis of 1,002 patients treated with the XIENCE V (PROMUS) Stent or
the TAXUS Express Stent. SPIRIT III is a large-scale, randomized,
non-inferiority, U.S. pivotal trial. The Company plans to issue a
press release at this time.
-- TAXUS ATLAS Small Vessels and Long Lesions studies. Nine-month data
from the TAXUS ATLAS global, multi-center studies will be presented at
a late-breaking trial session by the study's co-principal investigator
Mark A. Turco, M.D., at 1:00 p.m. in the main arena. Dr. Turco will
present clinical and angiographic follow-up data on patients treated
with the TAXUS Liberte 2.25 mm stent in small vessels (from the TAXUS
ATLAS Small Vessel study) and the TAXUS Liberte 38 mm stent in long
lesions (from the TAXUS ATLAS Long Lesion study). The Company plans to
issue a press release at this time.
-- TAXUS V de novo results. The Company
|SOURCE Boston Scientific Corporation|
Copyright©2007 PR Newswire.
All rights reserved